Search

Aqian Hu,1,&ast; Faping Li,2,&ast; Lei Guo,1 Xiaoxi Zhao,1 Xiaojun Xiang1 1Department of Psychiatry and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, 410011, People’s Republic of China; 2Department of Psychiatry, The Second People’s Hospital of Guizhou Province, Guiyang, 550004, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Xiaojun Xiang, Department of Psychiatry and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, 410011, People’s Republic of China, Tel +86-731-85295814, Email xiangxiaojun@csu.edu.cnObjective: Accumulating evidence has demonstrated that schizophrenia is associated with mitochondrial and immune abnormalities. In this pilot case–control study, we investigated the level of mitochondrial impairment in lymphocytes in patients with acute relapse of schizophrenia and explored the correlation between the level of mitochondrial damage and symptoms or treatment response.Methods: Lymphocytic mitochondrial damage was detected using mitochondrial fluorescence staining and flow cytometry in 37 patients (at admission and discharge) and 24 controls. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression Scale (CGI-S).Results: The levels of mitochondrial damage in CD3+ T, CD4+ T, and CD8+ T lymphocytes of the patients with schizophrenia at admission were significantly higher than those of the controls (p< 0.05) and did not return to normal at discharge (p> 0.05). The mitochondrial damage of T cells significantly improved at discharge for responsive patients only, as compared with that at admission (P< 0.05). However, no significant difference was found in mitochondrial damage in CD19+ B cells between patients and healthy controls, or between admission and discharge (p> 0.05).

Bin Liu,1 Faping Li,1 Mingdi Liu,2 Zhixiang Xu,2 Baoshan Gao,1 Yishu Wang,2 Honglan Zhou1 1Department of Urology, the First Hospital of Jilin University, Changchun, 130021, Jilin, People’s Republic of China; 2Key Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, 130021, Jilin, People’s Republic of ChinaCorrespondence: Yishu WangKey Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, 130021, Jilin, People’s Republic of China, Tel +86-18686686698Email wangys@jlu.edu.cnHonglan ZhouDepartment of Urology, the First Hospital of Jilin University, Changchun, 130021, Jilin, People’s Republic of ChinaTel +86 0431-81875821Email hlzhou@jlu.edu.cnBackground: Abnormal expression of phosphofructokinase platelet (PFKP) has been reported in various cancer types. However, the role of PFKP in clear cell renal cell carcinoma (ccRCC) remains unclear.Methods: In this study, the PFKP expression levels in various cancers were systemically described by integrating multiple kinds of publicly available databases. The relationship between PFKP expression and clinical prognosis of ccRCC patients was analyzed based on the TCGA database. Furthermore, PFKP-related genes and the top 10 hub genes were identified. The enrichment analysis, PPI network, and the relationship between PFKP and tumor-infiltrating immune cells were conducted to explore why PFKP was associated with clinical outcomes in ccRCC patients.Results: PFKP was significantly highly expressed in kidney cancer, especially in ccRCC. Moreover, patients with low expression of PFKP were correlated with poor 5-year and 10-year overall survival (OS) (P < 0.05). Low PFKP expression was a risk factor associated with decreased OS in subgroups including males, females, grade 3– 4, and stage III–IV (all P < 0.05). GO and KEGG enrichment analyses showed that 10 hub genes were mainly enriched in the tumor immune response. Finally, PFKP expression level was highly correlated